Abstract
In 1999, a biotech company was established in Västerbotten County, in Sweden, and given what was termed ‘all commercial rights’ to a major research biobank containing blood samples of the majority of the adult population. It was predicted that the company would place the otherwise rather marginalised community at the centre of international life-science research. International investments failed to appear, however. During the spring of 2002, internal disagreements concerning dispositional rights in the biobank resulted in court appeals, critical newspaper articles and, more informally, mutual threats among parties with different interests in the biobank material. In this article, it is argued that scrutiny of this conflict provides a chance to understand the emergence of delineated entitlements in material contained in Swedish biobanks.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
